(Total Views: 506)
Posted On: 01/12/2021 7:34:49 AM
Post# of 653
$RLFTF DD (copy) by OU2 on Ya-hoo-o Email received from Relief Investor Relations in response to an email I sent regarding the RS projections shared this past week.
It is clear from their response they were projecting midterm to long-term and not the immediate short-term (prior to top line results). In the direct quote below they used the term “future” as in not now. Here is the exact quote
“A reverse stock split on the Swiss stock exchange is certainly an option Relief may explore in the future or the issuance of an American depositary receipt (ADR). These steps would be taken in order to enable the Company to have a more attractive stock price per share. Relief will continue to evaluate this process in 2021 and update shareholders should more definitive plans take shape.”
So everyone needs to calm down. There are no definitive plans - meaning nothing immediate.
Furthermore, the language suggests they would not do anything now prior to RCT data reveal, and possibly not even until after EUA.
It appears that the 1/20 conversion was likely an illustration of what they can do to uplist, albeit the choice of timing and disclosing an exact ratio caused undo concern with investors.
RS is very likely but not until strength is established for the company.
There are multiple catalysts to tie a favorable RS to, such as EUA for IV formula, or Top Line for Inhaled formula, or full BLA for either.
To do it prior adds unnecessary stress on the share price, but a favorable RS with wind in our sails is an amazing opportunity that we should all support if you understand corporate finance.
Long RLFTF,
OU
It is clear from their response they were projecting midterm to long-term and not the immediate short-term (prior to top line results). In the direct quote below they used the term “future” as in not now. Here is the exact quote
“A reverse stock split on the Swiss stock exchange is certainly an option Relief may explore in the future or the issuance of an American depositary receipt (ADR). These steps would be taken in order to enable the Company to have a more attractive stock price per share. Relief will continue to evaluate this process in 2021 and update shareholders should more definitive plans take shape.”
So everyone needs to calm down. There are no definitive plans - meaning nothing immediate.
Furthermore, the language suggests they would not do anything now prior to RCT data reveal, and possibly not even until after EUA.
It appears that the 1/20 conversion was likely an illustration of what they can do to uplist, albeit the choice of timing and disclosing an exact ratio caused undo concern with investors.
RS is very likely but not until strength is established for the company.
There are multiple catalysts to tie a favorable RS to, such as EUA for IV formula, or Top Line for Inhaled formula, or full BLA for either.
To do it prior adds unnecessary stress on the share price, but a favorable RS with wind in our sails is an amazing opportunity that we should all support if you understand corporate finance.
Long RLFTF,
OU
(1)
(0)
$MJ
